abyssinone II: chemopreventive agent from Broussonetia papypera; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Broussonetia | genus | A plant genus of the family MORACEAE. Members contain PYRROLIDINES.[MeSH] | Moraceae | The mulberry plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. They have milky latex and small, petalless male or female flowers.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 10064832 |
| CHEMBL ID | 389924 |
| SCHEMBL ID | 3301551 |
| SCHEMBL ID | 13394426 |
| MeSH ID | M0499821 |
| Synonym |
|---|
| abyssinone ii |
| LMPK12140037 |
| CHEMBL389924 , |
| bdbm50213251 |
| (rac)-7-hydroxy-2-(4-hydroxy-3-(3-methylbut-2-enyl)phenyl)chroman-4-one |
| 7-hydroxy-2-[4''-hydroxy-3''-(3-methylbut-2-enyl)phenyl]chroman-4-one |
| 7-hydroxy-2-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]chroman-4-one |
| SCHEMBL3301551 |
| SCHEMBL13394426 |
| ncgc00385490-01!7-hydroxy-2-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]-2,3-dihydrochromen-4-one |
| 886620-61-7 |
| 7-hydroxy-2-(4-hydroxy-3-(3-methylbut-2-en-1-yl)phenyl)chroman-4-one |
| 7-hydroxy-2-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]-2,3-dihydrochromen-4-one |
| 7-hydroxy-2-(4-hydroxy-3-(3-methylbut-2-enyl)phenyl)chroman-4-one |
| DTXSID70904182 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Aromatase | Homo sapiens (human) | IC50 (µMol) | 34.5167 | 0.0000 | 1.2904 | 10.0000 | AID405556; AID405557; AID405558 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| negative regulation of chronic inflammatory response | Aromatase | Homo sapiens (human) |
| steroid biosynthetic process | Aromatase | Homo sapiens (human) |
| estrogen biosynthetic process | Aromatase | Homo sapiens (human) |
| androgen catabolic process | Aromatase | Homo sapiens (human) |
| syncytium formation | Aromatase | Homo sapiens (human) |
| negative regulation of macrophage chemotaxis | Aromatase | Homo sapiens (human) |
| sterol metabolic process | Aromatase | Homo sapiens (human) |
| female genitalia development | Aromatase | Homo sapiens (human) |
| mammary gland development | Aromatase | Homo sapiens (human) |
| uterus development | Aromatase | Homo sapiens (human) |
| prostate gland growth | Aromatase | Homo sapiens (human) |
| testosterone biosynthetic process | Aromatase | Homo sapiens (human) |
| positive regulation of estradiol secretion | Aromatase | Homo sapiens (human) |
| female gonad development | Aromatase | Homo sapiens (human) |
| response to estradiol | Aromatase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| iron ion binding | Aromatase | Homo sapiens (human) |
| steroid hydroxylase activity | Aromatase | Homo sapiens (human) |
| electron transfer activity | Aromatase | Homo sapiens (human) |
| oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | Aromatase | Homo sapiens (human) |
| oxygen binding | Aromatase | Homo sapiens (human) |
| heme binding | Aromatase | Homo sapiens (human) |
| aromatase activity | Aromatase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| endoplasmic reticulum | Aromatase | Homo sapiens (human) |
| endoplasmic reticulum membrane | Aromatase | Homo sapiens (human) |
| membrane | Aromatase | Homo sapiens (human) |
| endoplasmic reticulum | Aromatase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID405556 | Inhibition of aromatase by radiometric method | 2008 | Journal of natural products, Jun, Volume: 71, Issue:6 | Selective inhibition of aromatase by a dihydroisocoumarin from Xyris pterygoblephara. |
| AID405557 | Inhibition of aromatase by fluorimetric high throughput method | 2008 | Journal of natural products, Jun, Volume: 71, Issue:6 | Selective inhibition of aromatase by a dihydroisocoumarin from Xyris pterygoblephara. |
| AID419370 | Cytotoxicity against human MCF7 cells at 25 to 150 uM after 72 hrs by MTT assay | 2009 | European journal of medicinal chemistry, May, Volume: 44, Issue:5 | Synthesis of (+/-)Abyssinone I and related compounds: Their anti-oxidant and cytotoxic activities. |
| AID405558 | Inhibition of aromatase by fluorimetric method | 2008 | Journal of natural products, Jun, Volume: 71, Issue:6 | Selective inhibition of aromatase by a dihydroisocoumarin from Xyris pterygoblephara. |
| AID580924 | Cytotoxicity in human PC3M cells assessed as inhibition of cell proliferation upto 50 uM after 3 days by MTT assay | 2010 | ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8 | Concise syntheses of the abyssinones and discovery of new inhibitors of prostate cancer and MMP-2 expression. |
| AID419369 | Antioxidant activity assessed as DPPH radical scavenging activity at 200 ug after 30 mins by UV-visible spectrophotometry | 2009 | European journal of medicinal chemistry, May, Volume: 44, Issue:5 | Synthesis of (+/-)Abyssinone I and related compounds: Their anti-oxidant and cytotoxic activities. |
| AID419368 | Antioxidant activity assessed as ferric ion reducing activity at 200 ug after 20 mins by UV-visible spectrophotometry | 2009 | European journal of medicinal chemistry, May, Volume: 44, Issue:5 | Synthesis of (+/-)Abyssinone I and related compounds: Their anti-oxidant and cytotoxic activities. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.26) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||